Korea Investment CORP decreased its stake in shares of Celgene Co. (NASDAQ:CELG) by 8.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 795,265 shares of the biopharmaceutical company’s stock after selling 70,490 shares during the period. Korea Investment CORP owned 0.10% of Celgene worth $115,966,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Capital Counsel LLC NY increased its position in shares of Celgene by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC increased its position in shares of Celgene by 0.6% in the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 11 shares in the last quarter. Flagship Harbor Advisors LLC increased its position in shares of Celgene by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 18 shares in the last quarter. Savant Capital LLC increased its position in shares of Celgene by 0.9% in the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 20 shares in the last quarter. Finally, TCI Wealth Advisors Inc. increased its position in shares of Celgene by 0.9% in the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after acquiring an additional 26 shares in the last quarter. 79.84% of the stock is owned by hedge funds and other institutional investors.

Celgene Co. (NASDAQ:CELG) opened at $106.33 on Tuesday. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The company has a market cap of $83,720.00, a price-to-earnings ratio of 25.08, a price-to-earnings-growth ratio of 0.84 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the prior year, the firm posted $1.58 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. equities research analysts predict that Celgene Co. will post 6.68 earnings per share for the current fiscal year.

CELG has been the subject of a number of recent analyst reports. Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price target for the company. in a report on Tuesday, August 29th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene in a report on Monday, August 28th. Royal Bank of Canada reaffirmed a “buy” rating and set a $173.00 price target on shares of Celgene in a report on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and set a $162.00 price target on shares of Celgene in a report on Thursday, September 21st. Finally, Jefferies Group reaffirmed a “buy” rating and set a $160.00 price target on shares of Celgene in a report on Friday, September 15th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $135.17.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/12/26/celgene-co-celg-shares-sold-by-korea-investment-corp.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.